For a SaaS company, it's easier to move upmarket than down, and this gives SaaS startups the advantage against incumbents. In this episode,  David Ulevitch and our newest enterprise general partner Kristina Shen look at the SaaS go-to-upmarket with a focus on how to price for the move, including why so many founders underprice, how to think about free versus paid trials, and navigating the transition to larger accounts.  

Our understanding of the human brain and its disorders has always been limited by our lack of access to living, human, developing brain tissue. For the first time, that's changing. In this episode, Sergiu Pasca, Professor of Behavioral Science at Stanford, talks with a16'z General Partner Vijay Pande and Hanne Tidnam about the wild new tech that's pioneering a whole new approach to understanding the brain: brain organoids. So what are brain organoids, what are the scientific breakthroughs that lead to their creation, and how can we use them best? The conversation starts with the existing models we have used to learn about the living brain, from genetic studies to autopsies to primates—and what this new model now brings us: the ability to study the human brain, both how it develops and what goes wrong in certain disorders, with human brain tissue "alive" in a dish. We talk about what these organoids can and can’t do; what they’re good for understanding and where that understanding becomes limited; why calling these “brains in a dish” or “mini-brains” isn’t the right terminology at all; and finally, how far can this new tool and model be taken now and in the future, leading us closer towards understanding psychology itself on a molecular level. Image: Brain organoids derived in the Pasca Lab at Stanford University.